ASTRAZENECA PLC (AZN)
Health Care · Major Pharmaceutical Manufacturers · NYSE
AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline.
What ASTRAZENECA PLC does
AstraZeneca is a global, science-led biopharmaceutical company that discovers, develops, and commercializes prescription medicines. Its primary therapeutic areas include Oncology, Rare Disease, and BioPharmaceuticals (covering Cardiovascular, Renal & Metabolism, and Respiratory & Immunology). The company operates worldwide with a focus on delivering innovative treatments for some of the world's most serious diseases.
Recent developments
In October 2026, AstraZeneca completed a $2 billion equity investment in Summit Therapeutics to accelerate the development of the bispecific antibody ivonescimab in combination with its existing ADCs. Additionally, the company entered into clinical collaborations with Summit and Daiichi Sankyo to evaluate combinations of its cancer medicines, including datopotamab deruxtecan, with ivonescimab.
From ASTRAZENECA PLC's filing of 2026-10-05.
Themes: oncology innovation, rare disease therapeutics, biopharmaceutical R&D, personalized medicine, immunology, cardiovascular health
Fundamentals
- Price$168.82 as of 2026-10-20 close
- Market cap$254.2B market cap from Nasdaq, 2026-10-20
- 1-year return+0.6% 2025-10-20 close $167.74 → 2026-10-20 close $168.82
- P/En/a not reported by our data source
- Net margin+17.4% FY2025, SEC XBRL
- Gross margin+81.9% FY2025, SEC XBRL
- ROE+21.0% FY2025, SEC XBRL
- ROICn/a No figure: it does not file US-GAAP statements with the SEC.
- Debt / equityn/a No figure: it does not file US-GAAP statements with the SEC.
- Revenue growth (YoY)+8.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+9.8% SEC XBRL
- Beta0.34 as of 2026-09-03
- Last reported earningsn/a no confirmed date — as a foreign private issuer it reports on Form 6-K, which carries no earnings item code
Dividend: yield +2.6%; pays a dividend.
How AZN compares in its sector
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 63 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AZN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
56.0 #384 of 1,265 scored · #58 of 146 in Health Care
Profitability 79th (operating margin 23.4%, return on equity 21%) and financial health 75th (free cash flow margin 20%); weakest is valuation (30th, price to book 5.9). Scored on 5 of 6 pillars — it pays a dividend, but its filings carry no per-share series to count increases from; no annual share count in its filings.
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, AZN's dividend was covered by reported results (earnings payout 49%, free-cash-flow payout 42%). This describes past coverage, not a forecast.
- Earnings payout49% dividends / net income
- Free-cash-flow payout42% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How ASTRAZENECA PLC looks technically
ASTRAZENECA PLC (AZN) is trading 6.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 72 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-08-25, pushing above its recent trading range. It is 20.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.6% below its 200-day average, the long-term trend line — a long-term downtrend | -6.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $162.32 | $162.32 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $180.80 | $180.80 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 154. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 72 trading days ago — a "death cross", a bearish long-term signal | 72 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 60.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($154.00 to $169.81) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 93.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $212.71 | $212.71 |
|---|---|---|
| From the 52-week high | it is 20.6% below its 52-week high (its highest price of the past year) | -20.6% |
| Above the 52-week low | it is 10.0% above its 52-week low (its lowest price of the past year) | +10.0% |
| Below the 52-week high | it is 20.6% below its highest point of the past year | 20.6% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-08-25, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 55 trading days ago | 55 sessions |
| All-time high | its highest closing price on record is $212.71 (set on 2026-02-18) | $212.71 |
| Given back of the 52-week move | over the past year its closes ranged ($155.62 to $209.48), and it has recovered roughly a quarter of its fall from last year’s high — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $188.91 to $190.63. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 24.5% |
| From the all-time high | it is 20.6% below its all-time high | -20.6% |
| Nearest price level | it is trading 0.7% below a resistance level at $169.96 — a price it turned at three times since 2025-10-20, most recently on 2026-09-22. Since 2024-10-21 it has 8 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $21.54 (set on 1996-07-30) | $21.54 |
| Above the all-time low | it is 683.7% above its all-time low | +683.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 44th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.78 between its high and its low — about 2.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.78 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $154.09 and $169.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $154.09 – $161.76 – $169.42 |
| Typical daily range (% of price) | its price moves about 2.2% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.2% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges below its 200-day average price (6.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.37× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.2% since the prior reading | -0.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.7% |
|---|---|---|
| Open gap | it gapped 3.5% above the previous close 3 sessions ago and has not traded back through the level it left behind at 162.03 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.5% |
| Gap filled | a 2.1% gap up opened on 2026-10-06 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.7 percentage points (the stock gained 1.6% while the market gained 1.0%) | +0.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.0 percentage points (the stock gained 2.6% while the market gained 3.6%) | -1.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.4 percentage points (the stock lost 15.9% while the market gained 8.5%) | -24.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 13.9 percentage points (the stock gained 0.6% while the market gained 14.6%) | -13.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 7.8% of the share price. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $178.19 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -5.3% |
|---|
Double bottom, bullish — forming · entry $168.37 · 29 sessions in
Rectangle, either side — broke out · entry $167.01 · 54 sessions in
Descending triangle, either side — broke out · entry $165.77 · 58 sessions in
Double top, bearish — broke down · entry $156.94 · 39 sessions in
Price levels it has turned at before
AZN last closed at $168.82 on 2026-10-20. Since 2024-10-21 it has turned at 8 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $169.96 | Resistance | 0.7% above the last close | turned there three times · 2025-10-20 to 2026-09-22 |
| $166.79 | Support | 1.2% below the last close | turned there three times · 2025-10-16 to 2026-09-03 |
| $174.11 | Resistance | 3.1% above the last close | turned there four times · 2025-10-06 to 2026-07-29 |
| $163.24 | Support | 3.3% below the last close | turned there four times · 2025-08-22 to 2026-07-20 |
| $179.25 | Resistance | 6.2% above the last close | turned there five times · 2025-12-12 to 2026-05-15 |
| $157.38 | Support | 6.8% below the last close | turned there three times · 2025-03-05 to 2026-09-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $154.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 5 trading days, since 2026-10-14.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$206.83 range $158.00 – $240.00; median $209.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["high-stakes clinical trial failures in the R&D pipeline","intense competition from global pharmaceutical peers and generic manufacturers","significant regulatory and legal risks regarding drug safety, intellectual property, and pricing"]
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-161 buy ($3249) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-161 buy ($3249) · 1 sell ($2M) — 1 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-08. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AZN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 14 matched disclosures for AZN from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Short interest (FINRA)
AZN had 2,618,811 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for AZN because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 2,618,811
- Prior settlement (shares) 2,087,754
- Reported change 25.44%
- Days to cover (reported) 1
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (RHHBY)
- Novartis (NVS)
- Pfizer (PFE)
- Merck & Co. (MRK)
- Bristol Myers Squibb (BMY)
- GSK (GSK)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AZN vs…
ASTRAZENECA PLC is found in…
AZN shows up in…
Frequently asked questions
What does ASTRAZENECA PLC (AZN) do?
AstraZeneca is a global, science-led biopharmaceutical company that discovers, develops, and commercializes prescription medicines. Its primary therapeutic areas include Oncology, Rare Disease, and BioPharmaceuticals (covering Cardiovascular, Renal & Metabolism, and Respiratory & Immunology). The company operates worldwide with a focus on delivering innovative treatments for some of the world's most serious diseases.
What sector is ASTRAZENECA PLC (AZN) in?
ASTRAZENECA PLC (AZN) is classified in the Health Care sector. Its industry is Major Pharmaceutical Manufacturers. It trades on NYSE.
Does AZN pay a dividend?
Yes — ASTRAZENECA PLC (AZN) pays a dividend, with an indicated yield of about 2.58% (market data, as of 2026-09-03). Informational only — not financial advice.
Who are ASTRAZENECA PLC's (AZN) competitors?
Notable peers of ASTRAZENECA PLC (AZN) include Roche, Novartis, Pfizer, Merck & Co. and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in AZN?
Yes — we hold 14 matched STOCK Act disclosures for AZN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ASTRAZENECA PLC (AZN) overbought or oversold right now?
ASTRAZENECA PLC (AZN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AZN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.